Azenta, Inc. (AZTA) is a leading provider of consumables for life sciences and clinical research, offering a wide range of proprietary consumables that enable scientific analysis and discovery. The company is well-positioned in the life sciences ecosystem, interacting with both businesses and end-users in the pharmaceutical, biotechnology, academic and government sectors.
Their integrated solutions help to address the variety, velocity, and veracity of life sciences data. AZTA’s consumables products include various types of tubes, plates, sealing solutions, and custom barcode labeling solutions. These products are used in various applications, including sample collection, storage, track, and retrieval as well as automated sample handling systems.
Throughout its history, Azenta has been committed to innovation, advanced technology, and the highest level of service to help customers exceed their research and development goals. Their solutions are designed to assist scientists in managing, recovering, and detecting genomic and proteomic samples, thereby accelerating the pace of genetic discovery, drug development, and diagnostics.
The Company's innovative consumables, services, and informatics products support critical areas of research, development, and production in life sciences and clinical research, helping to increase productivity, enhance quality, and reduce cost. In the world of science where precision is paramount, Azenta delivers solutions that streamline processes, enhance productivity, and enable breakthrough discoveries.
Azenta, Inc. frequently engages in research and development efforts, regularly releasing new products or advancing existing solutions to better serve the needs of their clients. This innovation and dedication to its customers have enabled Azenta to work with some of the most well-known companies in the industry and establish itself as a trusted partner in the life sciences sector.
In conclusion, AZTA has a robust and diverse product offering that serves a multitude of sectors within the life sciences field. Their focus on innovation and commitment to quality sets them apart in their industry, positioning them as a leader in providing consumables for life sciences and clinical research. With their trendsetting products and impeccable service, Azenta, Inc. is poised to continue transforming the industry and facilitating scientific discovery and development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Azenta, Inc. has announced two strategic moves to enhance its DNA synthesis capabilities: an exclusive, royalty-free license agreement with Elegen Corp. for gene synthesis and cell-free cloning technology, and the acquisition of SynPlexity Inc., a firm specializing in DNA assembly technology. These transactions are expected to involve a capital investment of $32 million to $71 million and are aimed at advancing Azenta's GENEWIZ gene synthesis services and regional manufacturing capacity.

The Rosen Law Firm is investigating potential securities claims on behalf of Azenta, Inc. (NASDAQ: AZTA) shareholders due to allegations that the company may have issued misleading business information. This follows the resignation of Azenta's President and CEO, John P. Marotta, on August 22, 2026, which caused the stock to fall 12%. Investors who purchased Azenta securities are encouraged to contact the firm for information on joining a prospective class action.

This article provides a brief summary of Azenta Inc. (AZTA), a life sciences solutions provider. Argus issued a report on AZTA on September 30, 2026, and the current price is $34.09. The report suggests an upgrade to access premium tools and detailed insights for this company.

The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) following allegations of misleading business information. This investigation comes after Azenta's stock fell 12% on August 24, 2026, subsequent to the resignation of its President and CEO. Investors who purchased Azenta securities are encouraged to contact the firm regarding a potential class action to recover losses.